AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|
16.6 C
New York
Wednesday, October 28, 2026

Tag: itch

LA ROCHE-POSAY RAISES RM 100,000 TO NARROW MALAYSIA’S DERMATOLOGY CARE GAP

KUALA LUMPUR, Malaysia, June 18, 2025 /PRNewswire/ -- With fewer than 200 trained dermatologists serving Malaysia's 33 million people—just one specialist for every 165,000...

Cortizone-10® Partners with Dylan Efron and the National Park Foundation to Help Outdoor Enthusiasts Stay Itch-Free This Summer

The brand's new Itch Relief Cooling Spray helps tackle "itchsanity" one irritation at a time. MORRISTOWN, N.J., June 16, 2025 /PRNewswire/ -- Whether it's a...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsItch